Related Experiment Video
Updated: Oct 28, 2025
11:39
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
39.2K
Model-Based Meta-Analysis in Psoriasis: A Quantitative Comparison of Biologics and Small Targeted Molecules.
Huan He1, Wenwen Wu2, Yi Zhang1
1Clinical Research Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
Frontiers in Pharmacology
|July 19, 2021
Summary
This study compared 17 systemic agents for moderate to severe plaque psoriasis. Risankizumab and ixekizumab demonstrated superior efficacy for PASI75 and PASI90 endpoints.
Area of Science:
- Dermatology
- Pharmacology
- Biostatistics
Background:
- Information on the response time-course of biologics and small molecules for moderate to severe plaque psoriasis is limited.
- Clinicians need quantitative data on the efficacy of different systemic agents for psoriasis treatment.
Purpose of the Study:
- To quantitatively compare the efficacy of 17 systemic agents for moderate to severe plaque psoriasis.
- To analyze the time-course of drug response, including onset and maintenance of effect.
Main Methods:
- A model-based meta-analysis of 80 trials involving 40,323 patients was conducted.
- Longitudinal models were developed using Psoriasis Area and Severity Index 75 (PASI75) and PASI 90 (PASI90) endpoints.
- Drugs were categorized into five classes of biologics and three classes of small molecules.
Main Results:
- Risankizumab and ixekizumab showed the highest efficacy for PASI75 at week 12.
- Ixekizumab demonstrated the greatest PASI90 achievement at week 12, followed closely by risankizumab.
- Risankizumab provided the highest PASI90 response at weeks 16 and 24.
Conclusions:
- Risankizumab and ixekizumab were found to be superior for both PASI75 and PASI90 endpoints in treating moderate to severe plaque psoriasis.
- This study offers a quantitative efficacy comparison of systemic agents, excluding safety considerations.
Related Concept Videos
01:28Drug Products: Biologics, Biosimilars and Interchangeables
53
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
53
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
209
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
209